There are seven ratings firms that have a “buy” for Integra, with two equities analysts have the stock rated at a “hold”
Here are five quick facts about Integra LifeSciences stock:
• Average on-year target price among covering brokers is $61
• Barclays analysts raised their price target from $50 to $60
• Oppenheimer analysts reiterated their “outperform” rating and set a $62 price target
• Argus raised their price target from $55 to $61 with a “buy” rating on Feb. 13
• Integra has a $1.9 billion market cap and 58.26 price-to-earnings ratio
More articles on orthopedic device:
SI-BONE reaches 15k iFuse procedures—5 things to know
Globus Medical, Aurora Spine, NuVasive & more—22 key notes
Spine device company stock report: 5 key companies
